Trial Profile

Clinical study evaluating effect of BMN-333 for multiple growth disorders

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMN 333 (Primary)
Indications Growth disorders
Focus Adverse reactions; First in man

Most Recent Events

01 May 2025 Status changed from planning to active, no longer recruiting.
01 May 2025 According to BioMarin media release, the company enrolled multiple cohorts of healthy volunteers in its first-in-human study
19 Feb 2025 According to BioMarin media release,Initial pharmacokinetic data from this study is expected by year-end 2025, with detailed data to be presented at a scientific conference in the first half of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com